A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

ConditionPrimary Hypercholesterolemia

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age19+

SponsorAddpharma Inc.

About this trial

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Patients with Primary Hypercholesterolemia

Other inclusions applied

Disqualifiers

Patients with Secondary Hypercholesterolemia

Other exclusions applied

Trial design

Design model

Parallel

Treatments tested in this trial

AD-2281
Drug
PO, Once daily, 8weeks
AD-2282
Drug
PO, Once daily, 8weeks
Placebo of AD-2282
Drug
PO, Once daily, 8weeks

Treatment groups

110 Participants

are divided into 2 treatment groups

Group A: AD-2281 + AD-2282Experimental treatment 2 interventions

Group B: AD-2281 + Placebo of AD-2282Active comparator 2 interventions

Trial outcomes

Primary outcomes

Change rate of LDL-C

Percent change (%) of LDL-C from baseline at week 8

Time frame

from baseline at 8 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: